6-K 1 cns-10106k.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Date October 10, 2001 CeNeS Pharmaceuticals plc -------------------------------------------------------------------------------- (Translation of registrant's name into English) COMPASS HOUSE VISION PARK CHIVERS WAY HISTON CAMBRIDGE CB4 9ZR UNITED KINGDOM -------------------------------------------------------------------------------- (Address of principal executive office) (Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.) Form 20-F |X| Form 40-F |_| (Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.) Yes |_| No |X| 34427.0001 CeNeS Pharmaceuticals PLC 9 October 2001 CENES PHARMACEUTICALS PLC ("CeNeS " or "the Company") Re Directorate The board of CeNeS yesterday accepted the resignations of Dr Daniel Roach, the Company's chief executive officer, and Mr Martyn Collett, the Company's commercial director, with immediate effect as proposed in the Company's interim results announcement released on 1 October 2001. 9 October 2001 * * * * * 2 CeNeS Pharmaceuticals PLC 9 October 2001 CENES PHARMACEUTICALS PLC (the "Company") Director(s) Shareholding The Company was today informed that the following directors of the Company purchased a total of 499,999 ordinary shares of 10p each in the Company ("Ordinary Shares") on 5th October 2001, and a total of 2,293,887 Ordinary Shares on 8th October 2001. These purchases have been split as follows:

~~SIX~~Director/ ~~MONTHS~~Date(s) ~~ENDED~~of ~~Six~~Number ~~months~~of ~~ended~~Ordinary ~~Year~~Purchase ~~ended~~price ~~30TH~~per ~~JUNE~~% ~~30th~~interest ~~June~~following ~~31st~~Number ~~December~~interest ~~2001~~Shareholder ~~2000~~purchase ~~2000~~Shares purchased Ordinary Share (~~POUND~~p)~~'000~~ purchase(~~pound~~s)~~'000~~ following purchase(~~pound~~s)~~'000~~ ----------- -------- ---------------- ------------------ ----------- ---------------------~~------------------------------------~~ ~~Turnover~~A.G. ~~2,679~~Goodman ~~3,729~~5 ~~6,603~~Oct ~~Cost~~2001 of166,666 ~~sales~~10 (1~~,687)~~/4 ~~(443)~~5.32 (18,~~721)~~551,471* ~~Gross~~8 ~~profit~~Oct ~~992~~2001 3729,~~286~~562 ~~4,882~~9 ~~Research~~1/2 ~~and~~Dr ~~development~~D. ~~costs~~J. -Roach ~~continuing (~~5~~,386)~~ ~~(4,657)~~Oct (72001 166,~~785)~~666 -10 ~~licences~~1/4 ~~acquired~~5.32 ~~(10~~8,~~664) (12~~551,~~270)~~471* ~~(12,270)~~8 ~~Administrative~~Oct ~~expenses~~2001 (5729,~~492)~~562 (9 1/2~~,274)~~ ~~(6,254)~~N. ~~Operating~~R. ~~loss~~Clark ~~(20,550)~~8 ~~(15,915)~~Oct ~~(21~~2001 52,~~427)~~600 ~~Interest~~9 ~~receivable~~1/2 ~~(net)~~0.03 ~~100~~52,600 ~~332~~M. ~~603~~Collett ~~Loss~~8 onOct ~~ordinary~~2001 ~~activities~~52,600 ~~before~~9 ~~and~~1/2 ~~after~~0.04 ~~taxation (20~~56,~~450)~~661 ~~(15,583)~~ATM ~~(20,824)~~5 ~~Minority~~Oct ~~interest~~2001 2166,~~122~~667 -10 -1/4 ~~Loss~~4.77 ~~for the period (18~~7,~~328) (15~~655,~~583)~~243* ~~(20,824)~~8 ~~-------------------------------------------------------------------------------------------------------------------------~~Oct ~~Loss~~2001 ~~per~~729,563 ~~ordinary~~9 ~~share (12.0P) (17.2p) (20.9p) -------------------------------------------------------------------------------------------------------------------------~~1/2

Note: * 7,655,243 of these Ordinary Shares are held by ATM Global Investments Limited ("ATM"), a company controlled by A.G. Goodman and Dr D. J. Roach. 9 October 2001 * * * * * 3 CeNeS Pharmaceuticals PLC 9 October 2001 TO: CITY EDITORS 9th October, 2001 FOR IMMEDIATE RELEASE CeNeS Pharmaceuticals PLC Additional Listing Application has today been made to the UK Listing Authority for the admission to the Official List and to the London Stock Exchange for the admission to trading of 9,149,885 Ordinary Shares of 10 pence each in the capital of CeNeS Pharmaceuticals Plc ("CeNeS"). As announced with the interim results released on 1 October 2001, the shares have been subscribed for by Elan Corporation ("Elan"), at a price of 16.5 pence per share, in connection with an extension to the scope of the M6G/Medipad business venture agreement between CeNeS and Elan, whereby additional rights to M6G have been assigned by CeNeS to the business venture. The Shares will rank pari passu in all respects with the existing Ordinary Shares of 10 pence each. * * * * * 4 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CENES PHARMACEUTICALS PLC Date: October 10, 2001 By: /s/ Neil Clark ------------------------------------ Name: Neil Clark Title: Chief Operating Office and Finance Director 5

SIX MONTHS ENDED Six months ended Year ended 30TH JUNE 30th June 31st December 2001 2000 2000 (POUND)'000 (pound)'000 (pound)'000 ------------------------------------------------------------------------------------------------------------------------------ Fixed assets Intangible assets 54,243 22,379 56,917 Tangible assets 5,533 6,237 6,067 ------------------------------------------------------------------------------------------------------------------------------ 59,776 28,616 62,984 Current assets Stocks 634 36 349 Debtors 3,313 4,369 3,986 Cash at bank and in hand 4,749 13,771 10,561 ------------------------------------------------------------------------------------------------------------------------------ 8,696 18,176 14,896 ------------------------------------------------------------------------------------------------------------------------------ Creditors Creditors - amounts falling due within one year (4,952) (6,391) (7,616) ------------------------------------------------------------------------------------------------------------------------------ Net current assets 3,744 11,785 7,280 ------------------------------------------------------------------------------------------------------------------------------ Total assets less current liabilities 63,520 40,401 70,264 Creditors - amounts falling due after more than one year (9,869) (2,922) (2,668) ------------------------------------------------------------------------------------------------------------------------------ Net assets 53,651 37,479 67,596 ------------------------------------------------------------------------------------------------------------------------------ Capital and reserves Called up share capital 16,065 9,977 15,272 Share capital to be issued 5,262 5,262 5,307 Share premium account 84,929 51,454 81,473 Profit and loss account (63,026) (39,636) (44,877) Other reserves 10,421 10,422 10,421 ------------------------------------------------------------------------------------------------------------------------------ Equity shareholders' funds 53,651 37,479 67,596 Minority interests - - - ------------------------------------------------------------------------------------------------------------------------------ Total capital employed 53,651 37,479 67,596 ------------------------------------------------------------------------------------------------------------------------------

SIX MONTHS ENDED Six months ended Year ended 30TH JUNE 30th June 31st December 2001 2000 2000 (POUND)'000 (pound)'000 (pound)'000 ---------------------------------------------------------------------------------------------------------------------------- Net cash outflow from operating activities (9,820) (14,629) (17,760) ---------------------------------------------------------------------------------------------------------------------------- Returns on investments and servicing of finance Interest received 156 416 743 Interest paid (12) (16) (29) Interest element of finance lease rental payments (30) (68) (121) ---------------------------------------------------------------------------------------------------------------------------- Net cash inflow from returns on investment and servicing of finance 114 332 593 ---------------------------------------------------------------------------------------------------------------------------- Capital expenditure and financial investments Payment to acquire tangible fixed assets (154) (162) (298) Payment to acquire product licences (8,542) (10,252) - Receipts from sale of tangible fixed assets 13 82 69 ---------------------------------------------------------------------------------------------------------------------------- Net cash outflow from capital expenditure and financial investment (8,683) (80) (10,481) Acquisitions Purchase of subsidiary undertakings (1,234) - - Net cash acquired with subsidiary 123 4,685 - ---------------------------------------------------------------------------------------------------------------------------- Net cash inflow from acquisitions - 123 3,451 ---------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- Net cash outflow before financing (18,389) (14,254) (24,197) ---------------------------------------------------------------------------------------------------------------------------- Financing Issue of ordinary share capital 4,225 13,118 21,242 Costs associated with issue of shares (1,084) - - Issue of convertible loan note (net) 8,502 - - Grant receipts 56 - - Repayment of loans (32) (13) (45) Capital element of finance lease rentals (257) (288) (507) ---------------------------------------------------------------------------------------------------------------------------- Net cash inflow from financing 12,438 12,873 19,606 ---------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- Decrease in cash (5,951) (1,381) (4,591) ----------------------------------------------------------------------------------------------------------------------------

SIX MONTHS ENDED Six months ended Year ended 30 JUNE 30 June 31 December 2001 2000 2000 (POUND)'000 (pound)'000 (pound)'000 Operating loss (20,550) (15,915) (21,427) Depreciation 695 645 1,266 Amortisation of grant (21) (81) (51) Amortisation of goodwill 2,673 816 2,017 Amortisation of licence acquired 10,664 - - Loss on sale of tangible fixed assets 2 19 6 (Increase)/decrease in stocks (285) 40 (273) (Increase)/decrease in debtors 659 (3,703) (2,970) Increase/(decrease) in creditors (3,657) 3,550 3,672 -------------------------------------------------------------------------------------------------------------------------- Net cash outflow from operating activities (9,820) (14,629) (17,760) --------------------------------------------------------------------------------------------------------------------------

Filing Compare · CENES PHARMACEUTICALS PLC